- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04071821
Relative Bioavailability Study to Evaluate Cetirizine HCl Gummy 10 mg and Cetirizine HCl Oral Tablets 10 mg
February 6, 2023 updated by: Seattle Gummy Company
A Randomized, Open-Label, Single-Dose, Five-Period Crossover, Relative Bioavailability Study to Evaluate Cetirizine HCl Gummy 10 mg and Cetirizine HCl Oral Tablets 10 mg Administered in Healthy Adult Male and Female Subjects
A Randomized, Open-Label, Single-Dose, Five-Period Crossover, Relative Bioavailability Study to Evaluate Cetirizine HCl Gummy 10 mg and Cetirizine HCl Oral Tablets 10 mg Administered in Healthy Adult Male and Female Subjects
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Primary:
• To determine the relative bioavailability of a single oral dose of cetirizine HCl Gummy 10 mg and cetirizine HCl oral tablets 10 mg administered under fasted conditions in healthy adult male and female subjects.
Secondary:
- To determine the relative bioavailability of a single oral dose of cetirizine HCl Gummy 10 mg administered under fasted and fed conditions in healthy adult male and female subjects;
- To determine the relative bioavailability of a single oral dose of cetirizine HCl Gummy 10 mg administered under fasted conditions with and without water in healthy adult male and female subjects;
- To determine the relative bioavailability of a single oral dose of cetirizine HCl Gummy 10 mg administered under fasted conditions and chewed or swallowed whole in healthy adult male and female subjects.
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Are capable of giving informed consent and complying with study procedures;
- Male or female, 18 to 55 years of age, inclusive, at date of consent;
- Body mass index (BMI) ≥ 18.0 to ≤ 32.0 kg/m2 and total body weight > 50 kg (110 lbs.) at Screening;
All female subjects must have a negative pregnancy test at Screening and at each Check-in Visit; and one of the following:
- Using a medically acceptable form of birth control for at least 1 month prior to first dose [e.g., hormonal contraceptives (oral, patch, injectable or vaginal ring), intrauterine device, or a double barrier method (e.g., diaphragm, cervical cap, oral, patch or vaginal hormonal contraceptive, condom, spermicide, or sponge)]
- Documented as surgically sterile by hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/tubal occlusion) at least 6 months prior to the first dose;
- Postmenopausal (no menstruation for a minimum of 12 months and confirmed by FSH and estradiol at Screening);
- Medically healthy based on medical history, vital sign measurements, clinical laboratory test results, and physical examination;
- Non-smokers (including nicotine-containing products) for at least 6 continuous months prior to the first dose.
- Be willing and able to consume all contents of the standardized high calorie, high fat breakfast within 30 minutes prior to dosing.
Exclusion Criteria:
- Females who are pregnant, lactating, or planning to become pregnant during the study;
- Life-time history and/or recent evidence of alcohol or drug/substance abuse disorder;
- Subjects with history of hypersensitivity to cetirizine or hydroxyzine, or any component of the test and reference formulations;
- Subjects who test positive at Screening for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), or Hepatitis C virus (HCV) antibody;
- Subjects who test positive at Screening or at Check-in for alcohol and/or drugs of abuse;
- Subjects who donated ≥ 500 mL of blood within 56 days prior to the first dose of study drug or ≥ 50 mL and ≤ 499 mL of blood within 30 days or plasma (e.g. plasmapheresis) within 14 days prior to the first dose of study drug;
- Use of prescription or non-prescription drugs, dietary supplements, or herbal supplements at the time of Screening and within 14 days prior to the first dose of the study drug;
- Subjects who have a history of difficulty in donating blood or difficulty with phlebotomy procedures, and poor venous access;
- Subjects who have participated in another clinical trial within 30 days prior to the first study period;
- Member or first-degree relative of study staff or the Sponsor directly involved in the study;
- Any condition which in the opinion of Investigator would interfere with the subject's ability to provide informed consent, comply with study instructions, confound interpretation of study results, or endanger the subject if he or she took part in the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: A: Test under Fasted Condition
Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fasted conditions
|
cetirizine HCl 10mg in a gummy formulation
Other Names:
|
ACTIVE_COMPARATOR: B: Reference under Fasted Condition
Reference: Single oral dose of cetirizine HCl oral tablets 10 mg, administered with approximately 240 mL of room temperature water, under fasted conditions
|
cetirizine HCl 10mg tablet
|
EXPERIMENTAL: C: Test under Fed Condition
Test: Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fed conditions
|
cetirizine HCl 10mg in a gummy formulation
Other Names:
|
EXPERIMENTAL: D: Test under Fasted Condition with No Water
Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with no water, under fasted conditions
|
cetirizine HCl 10mg in a gummy formulation
Other Names:
|
EXPERIMENTAL: E: Test Swallowed Whole with Water, under Fasted Condition
Single oral dose of cetirizine HCl Gummy 10 mg, swallowed whole, administered with approximately 240 mL of room temperature water, under fasted conditions
|
cetirizine HCl 10mg in a gummy formulation
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
maximum plasma cetirizine concentration (Cmax)
Time Frame: 2 months
|
PK blood samples to measure plasma concentrations of cetirizine will be collected by direct venipuncture or by use of an indwelling cannula.
Blood will be collected into tubes containing K2EDTA for determination of plasma cetirizine concentration at time 0 (within 60 minutes pre-dose), 10, 20 minute post-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36 hours post-dose.
Plasma cetirizine concentrations will be listed at each time point by subject and summarized by treatment at each time point using descriptive statistics (n, mean, standard deviation (SD), Coefficient of variation (CV%), median, minimum and maximum values).
Pharmacokinetic calculations will be performed based on actual time of blood sample collection, using non-compartmental methods with Phoenix WinNonlin Version 8.1 (Certara USA, Inc., Princeton, New Jersey, USA).
Plots of mean concentrations of plasma cetirizine versus time will be generated and Cmax will be generated from the plot.
|
2 months
|
area under the plasma drug concentration versus time curve (AUC)
Time Frame: 2 months
|
AUC will be determined using non-compartmental analysis methods (Phoenix WinNonlin software, version 8.1 or higher, Certara USA Inc., Princeton, NJ).
AUC will be calculated to the last measurable observation (AUC0-t) and extrapolated to infinity (AUC0 ∞).
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
time to Cmax (Tmax)
Time Frame: 2 months
|
Tmax will be determined using non-compartmental analysis methods (Phoenix WinNonlin software, version 8.1 or higher, Certara USA Inc., Princeton, NJ).
|
2 months
|
elimination half-life (t½)
Time Frame: 2 months
|
t½ will be determined using non-compartmental analysis methods (Phoenix WinNonlin software, version 8.1 or higher, Certara USA Inc., Princeton, NJ).
|
2 months
|
terminal elimination rate constant (Kel).
Time Frame: 2 months
|
Kel will be determined using non-compartmental analysis methods (Phoenix WinNonlin software, version 8.1 or higher, Certara USA Inc., Princeton, NJ).
|
2 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
incidence of treatment-emergent adverse events (TEAE)
Time Frame: 2 months
|
Adverse events (AE) will be coded using a standardized Medical Dictionary for Regulatory Activities (MedDRA), Version 22,0 or higher.
All treatment-emergent adverse events (TEAE) will be documented throughout the study from the time a subject receives the first dose of study drug until 7 days after the subject receives the last dose of study drug.
|
2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
September 1, 2023
Primary Completion (ANTICIPATED)
December 15, 2023
Study Completion (ANTICIPATED)
April 30, 2024
Study Registration Dates
First Submitted
August 21, 2019
First Submitted That Met QC Criteria
August 26, 2019
First Posted (ACTUAL)
August 28, 2019
Study Record Updates
Last Update Posted (ACTUAL)
February 8, 2023
Last Update Submitted That Met QC Criteria
February 6, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P001-2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergy
-
University of RochesterNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingEgg Allergy | Food Allergy Peanut | Food Allergy in Infants | Allergy and Immunology | Peanut and Nut AllergyUnited States
-
Hong Kong Sanatorium & HospitalChinese University of Hong KongTerminatedAllergy to Fish | Allergy to Shrimp | Allergy to CrabHong Kong
-
King's College LondonGuy's and St Thomas' NHS Foundation TrustUnknownEgg Allergy | Food Allergy | Food Allergy in Children | Milk Allergy | Food Allergy in Infants | Nut Allergy | Food Allergen SensitisationUnited Kingdom
-
Abionic SAJohns Hopkins University; NAMSAWithdrawnAllergy | Allergic Asthma | Allergy to Cats | Allergy to House Dust | Allergy Cockroach | Allergy to Dog Dander (Finding) | Allergy MoldUnited States
-
Peking University Third HospitalCancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing... and other collaboratorsRecruitingCow Milk Allergy | Food Allergy in ChildrenChina
-
King's College LondonKing's College Hospital NHS Trust; University College London Hospitals; Cambridge... and other collaboratorsRecruitingEgg Allergy | Food Allergy | Food Allergy in Children | Milk Allergy | Food Allergy in Infants | Nut Allergy | Food Allergen SensitisationUnited Kingdom
-
Chinese University of Hong KongRecruiting
-
Martini Hospital GroningenRecruitingCow Milk Allergy | Food AllergyNetherlands
-
University GhentActive, not recruitingCow Milk Allergy | Food AllergyBelgium
-
Sayantani B. SindherNational Institute of Allergy and Infectious Diseases (NIAID)TerminatedAllergy;Food | Allergy to Shrimp | Allergy to Cashew Nut (Disorder)United States
Clinical Trials on cetirizine HCl Gummy
-
ShionogiCompletedSeasonal Allergic Rhinitis
-
Instituto de Investigación Hospital Universitario...Creaciones Aromáticas Industriales S.A.Completed
-
SightSage Foods and Nutrition Inc.Completed
-
Ohio State UniversityActive, not recruitingOral Cancer | Oral Health | Gum DiseaseUnited States
-
Indiana UniversityTerminatedExercise-induced Arterial HypoxemiaUnited States
-
Mylan Pharmaceuticals IncCompleted
-
University of California, DavisCompleted
-
Mylan Pharmaceuticals IncCompleted
-
Novartis PharmaceuticalsCompletedAllergic RhinitisCanada
-
Aleksandra StarkBrain Chemistry Labs, Institute for EthnomedicineActive, not recruiting